News and Updates

Agios Pharmaceuticals halts clinical development of tebapivat for sickle cell disease. Learn why the Phase 2 ENERGIZE trial results led to this decision.

IMUNON reports positive Phase 2 data for IMNN-001 in ovarian cancer, showing a significant reduction in residual disease post-surgery. Learn the details.

Armata Pharmaceuticals has submitted a Phase 3 trial protocol for AP-SA02, a novel bacteriophage therapy targeting life-threatening S. aureus bacteremia.

Is your clinical site compliant? Discover essential strategies for managing informed consent and avoiding FDA regulatory warnings in medical research.

AI-designed drugs are now entering clinical trials. Learn how these computational breakthroughs are navigating the critical bridge to human medicine.

Healx has begun human dosing for HLX-4310, a novel therapy for metastatic osteosarcoma. Discover how this AI-driven trial aims to transform bone cancer care.

New platforms are allowing bets on clinical trial outcomes, sparking ethical concerns among healthcare leaders about integrity and patient safety.

Ongoing conflict in the Middle East is stalling vital clinical trials. Discover how geopolitical instability is impacting patient safety and data integrity.

City of Hope launches a cutting-edge clinical trial to map how tumors evolve, aiming to overcome immunotherapy resistance and improve cancer patient outcomes.

New clinical trials for CAR T-cell therapy offer hope for T-cell lymphoma patients. Learn how precision gene-editing is transforming blood cancer treatment.